IC 51

Drug Profile

IC 51

Alternative Names: IC-51; Ixiaro; Japanese-encephalitis-purified-inactivated-vaccine-Valneva; JE-PIV; Jeev; Jespect; Jeval

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator VaccGen International LLC
  • Developer Adimmune Corporation; Biological E Limited; CSL; Valneva
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Japanese encephalitis
  • New Molecular Entity No

Highest Development Phases

  • Marketed Japanese encephalitis

Most Recent Events

  • 26 Jan 2016 IC 51 sub-licensed to GlaxoSmithKline in Germany
  • 26 Jan 2016 IC 51 sub-licensed to PaxVax in Italy, Spain and Portugal
  • 11 Jan 2016 Registered for Japanese encephalitis (Prevention) in Taiwan (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top